Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer
Breast Cancer|HER2 Positive
DRUG: paclitaxel, trastuzumab and carboplatin
Pathologic complete response (pCR) rate at surgery, at the completion of neo-adjuvant chemotherapy
To describe disease-free and overall survival, during routine follow up visits after surgery
To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer